Literature DB >> 19138543

Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.

Qing-Qing Xie1, Huan-Zhang Xie, Ji-Xia Ren, Lin-Li Li, Sheng-Yong Yang.   

Abstract

In this study, chemical feature based pharmacophore models of type I and type II kinase inhibitors of Tie2 have been developed with the aid of HipHop and HypoRefine modules within Catalyst program package. The best HipHop pharmacophore model Hypo1_I for type I kinase inhibitors contains one hydrogen-bond acceptor, one hydrogen-bond donor, one general hydrophobic, one hydrophobic aromatic, and one ring aromatic feature. And the best HypoRefine model Hypo1_II for type II kinase inhibitors, which was characterized by the best correlation coefficient (0.976032) and the lowest RMSD (0.74204), consists of two hydrogen-bond donors, one hydrophobic aromatic, and two general hydrophobic features, as well as two excluded volumes. These pharmacophore models have been validated by using either or both test set and cross validation methods, which shows that both the Hypo1_I and Hypo1_II have a good predictive ability. The space arrangements of the pharmacophore features in Hypo1_II are consistent with the locations of the three portions making up a typical type II kinase inhibitor, namely, the portion occupying the ATP binding region (ATP-binding-region portion, AP), that occupying the hydrophobic region (hydrophobic-region portion, HP), and that linking AP and HP (bridge portion, BP). Our study also reveals that the ATP-binding-region portion of the type II kinase inhibitors plays an important role to the bioactivity of the type II kinase inhibitors. Structural modifications on this portion should be helpful to further improve the inhibitory potency of type II kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138543     DOI: 10.1016/j.jmgm.2008.11.008

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  12 in total

1.  Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.

Authors:  Daniel Mucs; Richard A Bryce; Pascal Bonnet
Journal:  J Comput Aided Mol Des       Date:  2011-06-17       Impact factor: 3.686

2.  Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.

Authors:  Zhongjie Liang; Jing Ai; Xiao Ding; Xia Peng; Dengyou Zhang; Ruihan Zhang; Ying Wang; Fang Liu; Mingyue Zheng; Hualiang Jiang; Hong Liu; Meiyu Geng; Cheng Luo
Journal:  ACS Med Chem Lett       Date:  2013-02-25       Impact factor: 4.345

3.  1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies.

Authors:  Mohamed Hagras; Marwa A Saleh; Rogy R Ezz Eldin; Abdelrahman A Abuelkhir; Emad Gamil Khidr; Ahmed A El-Husseiny; Hesham A El-Mahdy; Eslam B Elkaeed; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

4.  Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies.

Authors:  Mohammed S Taghour; Hazem Elkady; Wagdy M Eldehna; Nehal M El-Deeb; Ahmed M Kenawy; Eslam B Elkaeed; Aisha A Alsfouk; Mohamed S Alesawy; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach.

Authors:  Kingkan Sanphanya; Suvara K Wattanapitayakul; Suwadee Phowichit; Valery V Fokin; Opa Vajragupta
Journal:  Bioorg Med Chem Lett       Date:  2013-03-20       Impact factor: 2.823

6.  Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.

Authors:  Marwa A Aziz; Rabah A T Serya; Deena S Lasheen; Amal Kamal Abdel-Aziz; Ahmed Esmat; Ahmed M Mansour; Abdel Nasser B Singab; Khaled A M Abouzid
Journal:  Sci Rep       Date:  2016-04-15       Impact factor: 4.379

7.  In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity.

Authors:  Ayman Abo Elmaaty; Khaled M Darwish; Amani Chrouda; Amira A Boseila; Mohamed A Tantawy; Sameh S Elhady; Afzal B Shaik; Muhamad Mustafa; Ahmed A Al-Karmalawy
Journal:  ACS Omega       Date:  2021-12-22

8.  Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.

Authors:  Abdallah E Abdallah; Reda R Mabrouk; Maged Mohammed Saleh Al Ward; Sally I Eissa; Eslam B Elkaeed; Ahmed B M Mehany; Mariam A Abo-Saif; Ola A El-Feky; Mohamed S Alesawy; Mohamed Ayman El-Zahabi
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

9.  New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.

Authors:  Abdallah E Abdallah; Reda R Mabrouk; Mohamed R Elnagar; Amel Mostafa Farrag; Mohamed H Kalaba; Mohamed H Sharaf; Esmail M El-Fakharany; Dina Abed Bakhotmah; Eslam B Elkaeed; Maged Mohammed Saleh Al Ward
Journal:  Drug Des Devel Ther       Date:  2022-03-03       Impact factor: 4.162

10.  Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer.

Authors:  Diaaeldin M Elimam; Abdullah A Elgazar; Fardous F El-Senduny; Ramadan A El-Domany; Farid A Badria; Wagdy M Eldehna
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.